Hematopoietically expressed homeobox gene is associated with type 2 diabetes in KK Cg-Ay/J mice and a Taiwanese Han Chinese population

CHI-CHENG LU1, YNG-TAY CHEN2,3, SHIH-YIN CHEN2,3, YUAN-MAN HSU4, CHYI-CHYANG LIN2, JE-WEI TSAO5, YU-NING JUAN2, JAI-SING YANG2 and FUU-JEN TSAI3,6,7

1Department of Pharmacy, Buddhist Tzu Chi General Hospital, Hualien 970002; 2Department of Medical Research; 3Human Genetics Center, Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40447; 4Department of Biological Science and Technology; 5School of Pharmacy, China Medical University, Taichung 40402; 6Department of Medical Genetics, China Medical University Hospital, Taichung 40447; 7School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan, R.O.C.

Received November 8, 2016; Accepted November 29, 2017

DOI: 10.3892/etm.2018.6152

Abstract. Diabetes mellitus (DM) is a chronic disease. The KK Cg-A/ J (KK-A) mouse is an animal model to study type 2 diabetes mellitus (T2D) disease. The present study assessed the expression of hematopoietically expressed homeobox (HHEX) protein in liver tissues of different age groups of mice (6, 16 and 42 weeks) by immunohistochemistry (IHC). The results demonstrated a significant decrease in the percentage of HHEX-positive cells in KK-A mice as compared with that in KK-α/α control mice. Furthermore, in Taiwan’s Han Chinese population, genotypic and allelic frequency distributions of the rs61862780 single-nucleotide polymorphism (SNP) in the HHEX gene were investigated. The results demonstrated that in the rs61862780 SNP of the 3'-untranslated region (UTR) of HHEX, the frequency of the CC genotype was higher in patients (6.0%) than in controls (2.7%), while the TT genotype frequency was about equal. In the same SNP, the frequency of the C allele was higher in patients (21.0%) than in controls (17.3%), while the T allele frequency was about equal. These results may pave the road for exploring the KK-Ay mouse model and the HHEX SNP rs61862780, which was correlated with the susceptibility to T2D in a Chinese population. Based on these findings, an association of HHEX gene expression with pathological features of T2D was indicated.

Introduction

Diabetes mellitus (DM) is a chronic disease with high prevalence in Taiwan (1,2). DM is characterized by a relative or absolute lack of insulin, resulting in hyperglycaemia (3). Chronic hyperglycaemia leads to a variety of complications such as neuropathy, nephropathy and retinopathy and increased risk of cardiovascular disease (4-7). According to the World Health Organization Global report, 422 million individuals were diagnosed with DM in 2016 (8). In Taiwan, DM was reported to be the fifth leading cause of death in 2015 by the Ministry of Health and Welfare of Taiwan (9). DM has two subtypes, namely type 1 and type 2 DM (10,11). Type 1 DM (T1D) is an autoimmune disease that leads to the destruction of the insulin-producing pancreatic β cells in the islets of Langerhans (12). In children and young adults, T1D is the most commonly diagnosed type of DM. T1D is associated with low endogenous insulin production in affected patients, and insulin supplementation by subcutaneous injection is required (13). The blood glucose levels must be frequently monitored to manage the risk of hypoglycaemia (14). Genetic influences and environmental factors have an important role in disease development (15,16). However, T2D is the most common type of DM in Taiwan. It is most commonly diagnosed in middle-aged adults (17). T2D is associated with insulin resistance, which is a lack of appropriate compensation by the β cells, leading to a relative insulin deficiency (18,19). In the early stage, insulin resistance may be improved by weight reduction and exercise (20). A variety of drugs are available for treating T2D (21,22). Treatment with drugs such as sulphonylureas stimulates insulin production by the β cells (23,24), while that with drugs such as biguanides or metformin reduces hepatic glucose production (25,26), while α-glucosidase inhibitors delay carbohydrate uptake in the gut (27,28), thiazolidinediones improve insulin action (29,30)
and as glucagon-like peptide 1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 inhibitors target the GLP-1 axis (31,32). DM represents a complex disease involving various bodily systems. Thus, animal models should be carefully selected, depending on what aspect of the disease is being investigated (33).

One of the mouse models that has not been extensively examined by the National Institutes of Health-sponsored Animal Models of Diabetic Complications Consortium is the KK Cg-A/J (KK-A') strain (34,35). The KK-A' mouse is a typical T2D model, and one of the inbred strains established from Japanese native mice (33,35). Yellow KK-A' mice carry the yellow obesity gene A' and develop marked adiposity and DM symptoms in comparison with control black KK-α/α mice (36). This model exhibits marked obesity, glucose intolerance and insulin resistance of peripheral tissue, hyperglycemia, dyslipidemia, hypertension and renal glomerular changes (33,35,36). Furthermore, the pancreatic islets in yellow KK-A' mice are hypertrophic and de-granulated. This mouse strain also presents with signs of diabetic nephropathy (33,35,36).

T2D is a phenotypically and genetically diverse disease characterized by insulin resistance (22,28). Candidate gene mapping and positional cloning have suggested numerous putative susceptibility variants, but only a few genetic variants leading to T2D have been clearly identified, including transcription-factor-7-like 2 (TCF7L2) and hematopoietically expressed homeobox (HHEX) protein (37-39). The HHEX gene is located on chromosome 10q23.33 and encodes a 270 amino-acid protein (40). HHEX contains the insulin-degrading enzyme (IDE) and kinesin family member 11 (40,41). The HHEX gene encodes a transcription factor involved in hepatic and pancreatic development via the Wnt signal pathway, which is fundamental for cell growth and differentiation (42,43). Numerous studies have identified the HHEX gene polymorphisms of rs1111875 T>C and rs7923837 A>G in T2D patients (38,44,45). A genome-wide scan for association provided evidence that HHEX is an excellent candidate susceptibility gene for T2D, and indicated a significant association of rs1111875 and rs7923837 with T2D (38). Although the association between HHEX polymorphisms and T2D has been well studied in humans, it has remained elusive in KK-α' mice. A preliminary study by our group clearly demonstrated that HHEX mRNA was downregulated in liver tissues of KK-α' mice as compared with that in KK-α/α control mice by complementary DNA microarray analysis (unpublished data). The present study focused on investigating the association between HHEX and T2D in KK-α' mice and in a Han Chinese Population in Taiwan.

**Materials and methods**

**KK-α/α and KK-α' mice.** A total of 5 four-week-old male control KK-α/α mice and 5 four-week-old male KK-α' mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA), the mice were divided into two groups (5 mice/group). The animals were housed in individual cages and provided lab chow (LabDiet 5k52; St. Louis, MO, USA) and water *ad libitum* in a room with a constant temperature (22-25°C), relative humidity (50-70%) and photoperiod (12-h light/dark cycle). The study was approved by the Institutional Animal Care and Use Committee of China Medical University (IACUC permit no. 102-217) as previously described (46).

**Immunohistochemical (IHC) analysis.** IHC was performed on paraffin-embedded liver sections as previously described (46,47). IHC staining for HHEX was performed using a Leica Bond MAX automated immunostainer (Leica Microsystems Inc., Buffalo Grove, IL, USA). Tissue sections (5-μm-thick) were de-waxed, treated with Proteinase K enzyme (cat. no. P2308; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), followed by blocking with 3% hydrogen peroxide (cat. no. H1009; Sigma-Aldrich; Merck KGaA). The slides were incubated in anti-HHEX (cat. no. GTX84369; Genetex, Hsinchu, Taiwan) antibodies (1:250 dilution) for 30 min at room temperature, followed by horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin G secondary antibodies (cat. no. 61-6520; 1:1,000; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 15 min at 37°C. Chromogen visualization was performed using 3,3'-diaminobenzidine tetrahydrochloride (DAB; cat. no. D12384, Sigma-Aldrich; Merck KGaA) for 5 min at room temperature. The sample was washed with 0.05% Tween 20 in Tris-buffered saline (DAKO, Carpenteria, CA, USA) between all steps.

**Patients and sample collection for genotyping.** A total of 570 patients diagnosed with T2D by endocrinologist at China Medical University Hospital (Taichung, Taiwan) were recruited between August 2014 and August 2015 for the present study from China Medical University Hospital. To compare the prevalence of polymorphisms in patients with that in a healthy population, the genotype frequency data of 1,700 healthy controls were downloaded from the Taiwan Biobank (https://taiwanview.twbiobank.org.tw/taiwanview/dl/do). The single nucleotide polymorphisms (SNPs) in the target gene were queried from the National Center of Biotechnology Information SNP database (http://www.ncbi.nlm.nih.gov/snp). The SNPs of the genes of interest were obtained and compared between the disease and control groups. Chi-square tests were used to calculate odds ratios and *P*-values. The study was approved by the ethics committee/Institutional Review Board of China Medical University Hospital (no. CMUH103-REC2-071).

**Statistical analysis.** The Chi-square test was used to determine statistically significant differences in allele/genotype frequencies of HHEX SNP rs61862780 between the case and control groups. Differences were considered statistically significant when *P*<0.05. The odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated for the genotypic and allelic frequencies of the HHEX SNP rs61862780. The statistical analysis was performed using SPSS version 11 (SPSS, Inc., Chicago, IL, USA).

**Results**

**Diabetes-associated features of yellow KK-α' mouse model.** The diabetes-associated features of yellow KK-α' mice according to the supplier's information and previous studies are listed in Table I (33,34). In the late stage (42 weeks), KK-α' mice presented with a variety of T2D-like characteristics,
including abnormal lipid homeostasis, increase in blood glucose levels, hyperglycemia (>400 mg/dl), glucose intolerance, increased circulating insulin and urine glucose levels, insulin resistance, adipose tissue weight increases, increased susceptibility to weight gain, abnormal morphology of pancreatic islets, renal glomerulus and renal tubules, de-granulated pancreatic β cells, dilated renal tubules, expanded mesangial matrix, increased renal glomerulus basement membrane thickness and hyaline cast present in tubules (2,21,31,33).

**HHEX protein expression in liver tissues of KK-α/α T2D model mice.** KK-α/α mice (control group) and KK-α/γ mice (T2D group) were individually sacrificed at 6, 16 and 42 weeks of age, and liver tissues were excised, fixed, embedded and sectioned for IHC staining. As presented in Fig. 1, IHC analysis indicated that the HHEX protein expression in liver tissue was decreased with time. Based on these results, HHEX protein expression in liver tissues of KK-α/γ mice (T2D group) was significantly lower than that in KK-α/α mice (control group). In addition, it was demonstrated that DM mice (KK-α/γ) grew in the period that relative HHEX protein expression were decreased (Fig. 2). Although KK-α/α mice (control group) grew in the same period HHEX protein expression did not change.

**Genotypic and allelic frequency distributions of the rs61862780 SNP in the HHEX gene among Taiwan’s Han Chinese population.** The genotypic and allelic frequency distributions of the rs61862780 SNP in the HHEX gene located within Chromosome 10q23.3 region (92,708,886 bp) are summarized in Table II. The Hardy-Weinberg model was used to describe and predict genotype and allele frequencies in the study cohort. It was observed that for the rs61862780 (C/T) SNP in the 3'-UTR of HHEX, the frequency of the CC genotype was higher in patients (6.0%) than in controls (2.7%). In addition, the frequency of the CT genotype was higher in patients (30.0%) than in controls (29.2%). In comparison with the TT genotype, the OR of the CC genotype was 2.4 (95% CI=1.51-3.8; P<0.001). The allelic frequency of the C allele was higher in patients (21.0%) than in controls (17.3%). In comparison with the T allele, the OR for the C allele was 1.27 (95% CI=1.08-1.5; P<0.005). It was therefore indicated that the HHEX SNP rs61862780 is associated with the susceptibility to T2D.

**Discussion**

Numerous animal models of T2D are obese to reflect the human condition where obesity is closely linked to T2D.
Table II. Genotypic and allelic frequencies in the rs61862780 single nucleotide polymorphism of the 3’ untranslated region of the HHEX gene in patients with T2D (n=570) and controls (n=1,698).

| Parameter | Patients with T2D, n (%) | Control, n (%) | OR (95% CI) P-value |
|-----------|--------------------------|----------------|---------------------|
| Genotype  |                          |                |                     |
| CC        | 34 (6.0)                 | 45 (2.7)       | 2.4 (1.51-3.8)*     | <0.001 |
| CT        | 171 (30.0)               | 496 (29.2)     | 1.09 (0.89-1.35)    |       |
| TT        | 365 (64.0)               | 1,157 (68.1)   |                     |       |
| Allele frequency |                |                |                     |
| C         | 239 (21)                 | 586 (17.3)     | 1.27 (1.08-1.5)*    | <0.005 |
| T         | 901 (79)                 | 2,810 (82.7)   |                     |       |

*Comparison with the TT genotype; †Comparison with the T-allele frequency. CI, confidence interval; OR, odds ratio; T2D, type 2 diabetes.

Figure 2. Cartoon representation of HHEX protein expression in KK-α/J mice (normal mice; black color) and KK Cg-A/J mice (T2D mice; yellow color) depending on the age of the mice. The amount of HEXX expression is indicated by + symbols. HHEX, hematopoietically expressed homeobox; T2D, type 2 diabetes.

Development (33). Two genetic mouse models of T2D exist, namely monogenic models (including Lepob/ob and Lepdb/db mice) and polygenic models (including KK Cg-A/J mice) (33). A variety of different polygenic mouse models of obesity, glucose intolerance and diabetes are available, and the variety of genotypes, for example KK Cg-A/J mice, which are one of the spontaneous animal models of T2D, might allow for more better modeling of T2D in humans compared with other obesity models (33,34,48). In the present study, KK-A’ mice were used to study the protein expression of HHEX in the liver. The KK-A’ mouse strain is glucose-intolerant, insulin-resistant, dyslipidemic and hypertensive (2,21,31). The complex pathogenesis of T2D in obese and non-obese patients involves genetic and environmental factors (49,50). Genome-wide association studies (GWAS) have indicated an association of T2D with several newly identified genes (51,52). Associations of T2D with common variants in HHEX, hepatocyte nuclear factor 4α, potassium voltage-gated channel subfamily J member 11 (KCNJ11), peroxisome proliferator-activated receptor γ, cyclin dependent kinase inhibitor 2A (CDK2A2)/2B, solute carrier family 30 member 8, cell division cycle 123 (CDC123)/calcium/calmodulin dependent protein kinase ID (CAMK1D), TCF7L2, ATP binding cassette subfamily A member 1 and solute-carrier-family-16-member 11 (SLC16A11) genes have been reported in European, Asian and Latin American populations (53-59). Kong et al (53,60,61) demonstrated associations of SNPs in woflargram ER transmembrane glycoprotein, CDK5 regulatory subunit associated protein 1 like 1, CDKN2A/2B, CDC123/CAMK1D, HHEX, TCF7L2, KCNQ1 and melatonin receptor 1B with T2D in a Chinese population. Sladek et al (62) reported variants of the TCF7L2, SLC30A8 and HHEX genes as novel loci associated with T2D by GWAS analysis in a French population. The present study proved that the frequency of the CC genotype of the rs61862780 (C/T) SNP in the 3’UTR of HHEX was higher in T2D patients than in controls compared with that of the TT genotype. In addition, the allelic frequency of the C allele was higher in patients than in controls compared with that of the T allele, which is in agreement with the previous studies (53,60,61). The HHEX gene regulates cell proliferation and tissue differentiation underlying vascular, hepatic differentiation and forebrain neuro-development (63-65). HHEX is essential for heart (66,67), thyroid (68), hepatic and pancreatic development and is a target of the Wnt signaling pathway (43,69). Decreased levels in HHEX-deficient islets cause disrupted paracrine inhibition of insulin release from β cells (70). HHEX activity has been described in the mouse lung, thyroid and liver. Numerous studies reported associations between HHEX/insulin-degrading enzyme variants (rs1111875) and the insulin secretion response following a glucose load, suggesting that the HHEX gene may influence the T2D risk primarily through an effect on β-cell function (47,71,72). However, to the best of our knowledge, HHEX protein expression has not been previously reported in KK-A’ T2D mice. The present study was the first to demonstrate the role of HHEX in KK-A’ mice. The IHC results were corroborated by results of a complementary DNA microarray analysis of the liver tissues (data not shown), which indicated a significant decrease in the expression of HHEX in KK-A’ mice at 16 and 42 weeks. High insulin levels (hyperinsulinemia) are a major feature of T2D in the early stage, and the pancreas fails to produce sufficient insulin to overcome the insulin resistance; however, failure of β-cell function in the late stages of T2D causes a reduction of insulin secretion (73,74). The present results suggested that downregulation of HHEX expression in the liver may contribute to disrupted paracrine
control of insulin secretion in KK-A′ T2D mice at 16 and 42 weeks.

Diabetes is a risk factor of various types of cancer, including colorectal cancer (CRC), as well as breast, bladder, liver and pancreatic cancer (75–77). Ma et al (54) demonstrated that T2D-associated variants of HHEX (rs7923837), TCF7L2 (rs290481) and CDKAL1 (rs7756992) increased the risk of cancer in patients with diabetes. Sun et al (78) also demonstrated that two variants on the T2D susceptibility gene HHEX are associated with the risk of CRC in a Chinese population. Therefore, the factors associated with an increased risk for CRC in T2D patients and the underlying mechanisms still require further study. The time-dependent changes in the protein levels of HHEX in KK-A′ T2D mice are summarized in Fig. 2. The present results demonstrated a downregulation of HHEX protein in the liver of KK-A′ T2D mice and an association of the HHEX SNP rs61862780 with T2D in Taiwanese populations, indicating that loss/mutation of HHEX may have an important role in the pathogenesis of T2D.

Acknowledgements
Not applicable.

Funding
This study was supported by the Biosignature project, Academia Sinica, Taiwan and the China Medical University Hospital (Taichung, Taiwan; grant no. DMR-107-123).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
CCLU, JSY and FJT conceived and designed the experiments. JWT and YNJ performed the experiments. YTC, SYC, YMH modified the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The animal experiments were approved by the Institutional Animal Care and Use Committee of China Medical University (IACUC permit no. 102-217). The human experiments were approved by the ethics committee/Institutional Review Board of China Medical University Hospital (no. CMUH103-REC2-071).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Hou WH, Li CY, Chen LH, Wang LY, Kuo KN, Shen HN and Chang MF: Prevalence of hand syndromes among patients with diabetes mellitus in Taiwan: A population-based study. J Diabetes 9: 622-627, 2017.
2. Chen SY, Hsu YM, Lin YJ, Huang YC, Chen CJ, Lin WD, Liao WL, Chen YT, Lin WY, Liu YH, et al: Current concepts regarding developmental mechanisms in diabetic retinopathy in Taiwan. Biomedicine (Taipei) 6: 7, 2016.
3. Middleton P, Crowther CA and Simmonds L: Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev: CD008540, 2016.
4. Adeshara KA, Diwan AG and Tupe RS: Diabetes and complications: Cellular signaling pathways, current understanding and targeted therapies. Curr Drug Targets 17: 1309-1329, 2016.
5. Zatalia SR and Sanusi H: The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones 45: 141-147, 2013.
6. Resi M and Clodi M: Diabetes and cardiovascular complications. Wien Med Wochenschr 160: 3-7, 2010 (In German).
7. Hah R and Moltch ME: Diabetes, cardiovascular risk and nephropathy. Cardiol Clin 28: 467-475, 2010.
8. World Health Organization: Global report on diabetes. WHO, Geneva, 2016. http://www.who.int/diabetes/global-report/en/.
9. Ministry of Health and Welfare: 2015 statistics of causes of death. Ministry of Health and Welfare, Taiwan, R.O.C. https://www.mohw.gov.tw/cp-3265-30093-2.html. Last Updated July 18, 2017.
10. Yang X, Xu Z, Zhang C, Cai Z and Zhang J: Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells. Biochim Biophys Acta 1863: 1984-1990, 2017.
11. Murillo-Maldonado JM and Riesgo-Escovar JR: Development and diabetes on the fly. Mech Dev 144: 150-155, 2017.
12. Boldison J and Wong FS: Immune and pancreatic β cell interactions in type 1 diabetes. Trends Endocrinol Metab 27: 856-867, 2016.
13. Kesavadev J: Insulin pump therapy in pregnancy. J Pak Med Assoc 66 (9 Suppl 1): S39-S44, 2016.
14. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J and Weigtasser R: Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial. Lancet 388: 2254-2263, 2016.
15. Zou D, Ye Y, Zou N and Yu J: Analysis of risk factors and their interactions in type 2 diabetes mellitus: A cross-sectional survey in Guilin, China. J Diabetes Investig 8: 188-194, 2017.
16. Hotta-Iwamura C and Tarbell KV: Type 1 diabetes genetic susceptibility and dendritic cell function: Potential targets for treatment. J Leukoc Biol 100: 65-80, 2016.
17. Cheng CA, Chien WC, Hsu CY, Lin HC and Chiu HW: Risk of diabetes in type 2 diabetes: A population-based database in Taiwan. Medicine (Baltimore) 95: e4747, 2016.
18. Sakai S, Tanimoto K, Imbe A, Inaba Y, Shishikura K, Tanimoto Y, Ushiroyama T, Terasaki J and Hanafusa T: Decreased β-cell function is associated with reduced skeletal muscle mass in Japanese subjects without diabetes. PLoS One 11: e0162603, 2016.
19. Rezai S, LoBue S and Henderson CE: Diabetes prevention: Reproductive age women affected by insulin resistance. Womens Health (Lond) 12: 427-432, 2016.
20. Arias-Loste MT, Ranchal I, Romero-Gómez M and Crespo J: Iirisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci 15: 23163-23178, 2014.
21. Skliros NP, Vlahopoulos C and Tousoulis D: Treatment of diabetes: Crossing to the other side. Hellenic J Cardiol 57: 304-310, 2016.
22. Marín-Peñalver JJ, Martín-Timón I, Sevilla-Collantes C and Del Cañizo-Gómez F: Update on the treatment of type 2 diabetes mellitus. World J Diabetes 7: 354-395, 2016.
23. Nelquin M and Henquin JC: Sulphonylurea receptor-1, sulphonylureas and amplification of insulin secretion by Epac activation in β cells. Diabetes Obes Metab 18: 698-701, 2016.
24. Abdelmonem AI, Welsh RC, Euirich DT and Simpson SH: Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction. Int J Cardiol 202: 126-130, 2016.
25. Winkler G: Metformin-new data for an ‘old’, but efficient, safe and reliable antidiabetic drug. Orv Hetil 157: 882-891, 2016.
26. De Souza A, Khawaja KI, Masud F and Saif MW: Metformin and pancreatic cancer: Is there a role? Cancer Chemother Pharmacol 77: 235-242, 2016.

27. Zhang L, Chen Q, Li L, Kwong JS, Jia P, Zhao P, Wang W, Zhou X, Zhang M and Sun X: Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: A systematic review and meta-analysis. Sci Rep 6: 32649, 2016.

28. Smith JD, Mills E and Carlisle SE: Treatment of pediatric type 2 diabetes. Ann Pharmacother 50: 768-777, 2016.

29. Ahlund V: Novel targets and pathways for diabetes: Uptake, usage trends, and comparative effectiveness. Curr Diab Rep 16: 47, 2016.

30. Salazar JJ, Ennis WJ and Koh TF: Diabetes medications: Impact on inflammation and wound healing. J Diabetes Complications 30(1): 94-100, 2016.

31. Bae EJ: DPP-4 inhibitors in diabetic complications: Role of DPP-4 beyond glucose control. Arch Pharm Res 39: 1114-1128, 2016.

32. Bonora E and Cigolini M: DPP-4 inhibitors and cardiovascular diseases in type 2 diabetes mellitus. Expectations, observations and perspectives. Nutr Metab Cardiovasc Dis 26: 273-284, 2016.

33. King AJ: The use of animal models in diabetes research. Br J Pharmacol 166: 877-894, 2012.

34. O'Brien SP, Smith M, Ling H, Phillips L, Weber W, Lydon J, Maloney C, Ledbetter S, Arbeezy C and Wawersik S: Glucogenolysis in the KK-CeAc/H mouse reflects the pathology of diabetic nephropathy. J Diabetes Res 2013: 498925, 2013.

35. Ikeda H: KK mouse. Diabetes Res Clin Pract 24 (Suppl): S33-S331, 1995.

36. Iwasuka H, Shino A and Suzuki Z: General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17: 23-35, 1970.

37. Wang Y, Qiao W, Zhao X and Tao M: Quantitative assessment of the influence of hematopoietically expressed homeobox variant (rns111875) on type 2 diabetes risk. Mol Genet Metab 102: 194-199, 2011.

38. van Vliet-Ostaptchouk JV, Onland-Moret NC, van Haeften TW, Franke L, Elbers CC, Shiri-Sverdlow R, van der Schouw YT, van Vliet-Ostaptchouk JV, Onland-Moret NC, van Haeften TW, Imamura M, Kato T, Klimentidis YC, Lemas DJ, Wiener HH, O'Brien DM, Havel PJ, Stanhope KL, Hopkins SE, Tiwari HK and Boyer BB: CDKAL1 and HHEX are associated with type 2 diabetes-related traits among Yupik people. J Diabetes 6: 251-259, 2014.

39. Solanow DA, Ortega K, Haffner SM, Wanger GS, Mehra MR, Muhlivil JJ, Ferrell RE, Nath SK and Kamboh MI: Impact of nine common type 2 diabetes risk polymorphisms on Asian Indian Sikhs: PPARG2 (Pro12Ala), IGFB2P2, TCF7L2 and FTO variants confer a significant risk. BMC Med Genet 9: 59, 2008.

40. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al.: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316: 1343-1345, 2007.

41. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, et al.: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331-1336, 2007.

42. Malhotra A, Coon H, Feitosa MF, Li WD, North KE, Price RA, Bouchard C, Hunt SC and Woldford JK; American Diabetes Association GENNID Study Group: Meta-analysis of genome-wide linkage studies for quantitative lipid traits in type 2 diabetes: Implication in personalized medicine. DNA Cell Biol 35: 1-12, 2016.

43. Cornelis MC, Zaitlen N, Hu FB, Kraft P and Price AL: Genetic and environmental components of family history in type 2 diabetes. Hum Genet 134: 259-267, 2015.

44. Flannick J and Florez JC: Type 2 diabetes: Genetic data sharing to advance complex disease research. Nat Rev Genet 17: 535-549, 2016.

45. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwal V, Gaulton M, M C, Singh M, Moulson L, McCarthy DJ, et al.: The genetic architecture of type 2 diabetes. Nature 536: 41-47, 2016.

46. Kong X, Zhang X, Xing X, Zhang Z, Hong J and Yang W: The association of type 2 diabetes loci identified in genome-wide association studies with metabolic syndrome and its components in a Chinese population with type 2 diabetes. PLoS One 10: e0143607, 2015.

47. Ma RC, So WY, Tam CH, Luk AO, Ho JS, Wang Y, Lam VK, Lee HM, Kong AP, Tong PC, et al.: Genetic variants for type 2 diabetes and new-onset cancer in Chinese with type 2 diabetes. Hum Genet 135: 289-297, 2015.
67. Foley AC and Mercola M: Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. Genes Dev 19: 387-396, 2005.
68. Liu S, Chai J, Zheng G, Li H, Lu D and Ge Y: Screening of HHEX mutations in Chinese children with thyroid dysgenesis. J Clin Res Pediatr Endocrinol 8: 21-25, 2016.
69. McLin VA, Rankin SA and Zorn AM: Repression of Wnt/beta-catenin signaling in the anterior endoderm is essential for liver and pancreas development. Development 134: 2207-2217, 2007.
70. Zhang J, McKenna LB, Bogue CW and Kaestner KH: The diabetes gene Hhex maintains δ-cell differentiation and islet function. Genes Dev 28: 829-834, 2014.
71. Rong R, Hanson RL, Ortiz D, Wiedrich C, Kobes S, Knowler WC, Bogardus C and Baier LJ: Association analysis of variation in near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians. Diabetes 58: 478-488, 2009.
72. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, et al: Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57: 2503-2510, 2008.
73. Chiasson JL: Early insulin use in type 2 diabetes: What are the cons? Diabetes Care 32 (Suppl 2): S270-S274, 2009.
74. Fonseca VA: Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 (Suppl 2): S151-S156, 2009.
75. Vigneri R, Goldfine ID and Frittitta L: Insulin, insulin receptors, and cancer. J Endocrinol Invest 39: 1365-1376, 2016.
76. de Miguel-Díez J, Muñoz-Rivas N, Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, Monreal M, Jiménez D, Guitarro R and López de Andrés A: Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004-2013. Respirology 21: 1277-1284, 2016.
77. Yu F, Guo Y, Wang H, Feng J, Jin Z, Chen Q, Liu Y and He J: Type 2 diabetes mellitus and risk of colorectal adenoma: A meta-analysis of observational studies. BMC Cancer 16: 642, 2016.
78. Sun R, Liu JP, Gao C, Xiong YY, Li M, Wang YP, Su YW, Lin M, Jiang AL, Xiong LF, et al: Two variants on T2DM susceptible gene HHEX are associated with CRC risk in a Chinese population. Oncotarget 7: 29770-29779, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.